enVVeno Medical Narrows Q2 Loss 46%, Extends Cash Runway to Q3 2027 as Pivotal Trial Nears

summarizeSummary

enVVeno Medical reported a 46% narrower Q2 net loss of $3.6 million and extended its cash runway to Q3 2027, while confirming the pivotal trial for its enVVe venous valve will begin later this year.

check_boxKey Events · Earnings and Guidance · NVNO

• Q2 Loss Narrows 46%

  Net loss fell to $3.6 million from $6.7 million a year ago, driven by lower R&D and SG&A expenses as the VenoValve study winds down.

• Cash Runway Extended to Q3 2027

  Cash and investments totaled $21.5 million at June 30, 2026. Management expects the burn rate to rise to $4–5 million per quarter in H2 2026 but still sees funding into Q3 2027.

• Pivotal Trial to Start H2 2026

  FDA IDE approval was received in April 2026. The first 10-patient stage of the TAVVE study is expected to commence in the second half of 2026, with 30-day safety data submitted to the FDA.

• Minimal ATM Dilution in Q2

  Only 17,000 shares were issued under the at-the-market program during the quarter, raising net proceeds of $0.1 million.

auto_awesomeAnalysis · NVNO · Industrial Applications And Services

enVVeno Medical cut its quarterly net loss nearly in half to $3.6 million while holding $21.5 million in cash and investments — enough to fund operations into the third quarter of 2027. The company also confirmed FDA approval of its IDE for the enVVe venous valve pivotal study, with the first 10-patient stage expected to begin in the second half of 2026. The improved burn rate and extended runway reduce near-term dilution risk, but the company still needs to raise additional capital before commercialization.